Cargando…

Risk factors for the discontinuation of roflumilast in patients with chronic obstructive pulmonary disease

INTRODUCTION: Roflumilast is a phosphodiesterase-4 inhibitor, which can decrease exacerbation in patients with chronic obstructive pulmonary disease (COPD). However, adverse effects are a major barrier to medication use, and little is known regarding the risk factors for discontinuation of roflumila...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Kyung Hoon, Kang, Hye Seon, Kim, Ju Sang, Yoon, Hyoung Kyu, Kim, Sung Kyoung, Rhee, Chin Kook
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2017
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5720347/ https://www.ncbi.nlm.nih.gov/pubmed/29270006 http://dx.doi.org/10.2147/COPD.S143967

Ejemplares similares

Incidence of Adverse Effects and Discontinuation Rate between Patients Receiving 250 Micrograms and 500 Micrograms of Roflumilast: A Comparative Study
por: Joo, Hyonsoo, et al.
Publicado: (2018)

Comparison of clinical characteristics and overall survival between spirometrically diagnosed chronic obstructive pulmonary disease (COPD) and non-COPD never-smoking stage I-IV non-small cell lung cancer patients
por: Lim, Jeong Uk, et al.
Publicado: (2019)

Association between Serum Levels of Interleukin-25/Thymic Stromal Lymphopoietin and the Risk of Exacerbation of Chronic Obstructive Pulmonary Disease
por: Choi, Joon Young, et al.
Publicado: (2023)

Effect of a Dose-Escalation Regimen for Improving Adherence to Roflumilast in Patients with Chronic Obstructive Pulmonary Disease
por: Hwang, Hyunjung, et al.
Publicado: (2015)

Comparison of clinical characteristics between chronic bronchitis and non-chronic bronchitis in patients with chronic obstructive pulmonary disease
por: Choi, Joon Young, et al.
Publicado: (2022)

Nationwide quality assessment of treatment for chronic obstructive pulmonary disease
por: Kim, Kyu Yean, et al.
Publicado: (2020)

Effect and safety of roflumilast for chronic obstructive pulmonary disease in Chinese patients
por: Liu, Dong-yang, et al.
Publicado: (2018)

Factors associated with plasma IL-33 levels in patients with chronic obstructive pulmonary disease
por: Kim, Sei Won, et al.
Publicado: (2017)

Development of a daily predictive model for the exacerbation of chronic obstructive pulmonary disease
por: Jo, Yong Suk, et al.
Publicado: (2023)

Roflumilast: the evidence for its clinical potential in the treatment of chronic obstructive pulmonary disease
por: Wagner, Linda Timm, et al.
Publicado: (2005)

Role of phosphodiesterase-4 inhibitors in chronic obstructive pulmonary disease
por: Rhee, Chin Kook, et al.
Publicado: (2020)

Association between plasma interleukin-33 level and acute exacerbation of chronic obstructive pulmonary disease
por: Joo, Hyonsoo, et al.
Publicado: (2021)

The association between eosinophilic exacerbation and eosinophilic levels in stable COPD
por: Kang, Hye Seon, et al.
Publicado: (2021)

Correction to: Association between plasma interleukin-33 level and acute exacerbation of chronic obstructive pulmonary disease
por: Joo, Hyonsoo, et al.
Publicado: (2021)

Evaluation of asthma–chronic obstructive pulmonary disease overlap using a mouse model of pulmonary disease
por: Jo, Yong Suk, et al.
Publicado: (2022)

Correction: Evaluation of asthma–chronic obstructive pulmonary disease overlap using a mouse model of pulmonary disease
por: Jo, Yong Suk, et al.
Publicado: (2023)

Chronic Obstructive Pulmonary Disease-Related Non-Small-Cell Lung Cancer Exhibits a Low Prevalence of EGFR and ALK Driver Mutations
por: Lim, Jeong Uk, et al.
Publicado: (2015)

Summary of the Chronic Obstructive Pulmonary Disease Clinical Practice Guideline Revised in 2014 by the Korean Academy of Tuberculosis and Respiratory Disease
por: Yoon, Hyoung Kyu, et al.
Publicado: (2017)

Direct and Indirect Costs of Chronic Obstructive Pulmonary Disease in Korea
por: Kim, Changhwan, et al.
Publicado: (2019)

The health-related quality-of-life of chronic obstructive pulmonary disease patients and disease-related indirect burdens
por: Choi, Hye Sook, et al.
Publicado: (2020)

Racial Differences in Prevalence and Clinical Characteristics of Asthma–Chronic Obstructive Pulmonary Disease Overlap
por: Jo, Yong Suk, et al.
Publicado: (2021)

Clinical Role of the Chronic Obstructive Pulmonary Disease Assessment Test in Prediction of the Response to Treatment for Exacerbations
por: Yoon, Sunyoung, et al.
Publicado: (2019)

Frequent Outpatient Visits Prevent Exacerbation of Chronic Obstructive Pulmonary Disease
por: Park, Hye Jung, et al.
Publicado: (2020)

The health care burden of high grade chronic obstructive pulmonary disease in Korea: analysis of the Korean Health Insurance Review and Assessment Service data
por: Kim, JinHee, et al.
Publicado: (2013)

High prevalence of chronic obstructive pulmonary disease in Korea
por: Rhee, Chin Kook
Publicado: (2016)

Association between chronic obstructive pulmonary disease and gastroesophageal reflux disease: a national cross-sectional cohort study
por: Kim, Jinhee, et al.
Publicado: (2013)

Mortality of patients with chronic obstructive pulmonary disease: a nationwide populationbased cohort study
por: Park, Seon Cheol, et al.
Publicado: (2019)

Effectiveness of Roflumilast in Treating Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis
por: Naseem, Sumbal, et al.
Publicado: (2022)

Chronic cough as a novel phenotype of chronic obstructive pulmonary disease
por: Koo, Hyeon-Kyoung, et al.
Publicado: (2018)

Comparison of the clinical characteristics and treatment outcomes of patients requiring hospital admission to treat eosinophilic and neutrophilic exacerbations of COPD
por: Kang, Hye Seon, et al.
Publicado: (2016)

Longitudinal changes in forced expiratory volume in 1 s in patients with eosinophilic chronic obstructive pulmonary disease
por: Jo, Yong Suk, et al.
Publicado: (2022)

Diaphragm Ultrasound is an Imaging Biomarker that Distinguishes Exacerbation Status from Stable Chronic Obstructive Pulmonary Disease
por: An, Tai Joon, et al.
Publicado: (2022)

Short-term Evaluation of a Comprehensive Education Program Including Inhaler Training and Disease Management on Chronic Obstructive Pulmonary Disease
por: Yoo, Kwang Ha, et al.
Publicado: (2017)

Phenotype of asthma-chronic obstructive pulmonary disease overlap syndrome
por: Rhee, Chin Kook
Publicado: (2015)

The global status of chronic obstructive pulmonary disease
por: Rhee, Chin Kook, et al.
Publicado: (2021)

Risk factors for early readmission after acute exacerbation of chronic obstructive pulmonary disease
por: Jo, Yong Suk, et al.
Publicado: (2020)

Factors associated with chronic obstructive pulmonary disease exacerbation, based on big data analysis
por: Lee, Jongmin, et al.
Publicado: (2019)

Characteristics of Patients with Chronic Obstructive Pulmonary Disease at the First Visit to a Pulmonary Medical Center in Korea: The KOrea COpd Subgroup Study Team Cohort
por: Lee, Jung Yeon, et al.
Publicado: (2016)

Different anti-remodeling effect of nilotinib and fluticasone in a chronic asthma model
por: Kang, Hye Seon, et al.
Publicado: (2016)

Lower 30-day readmission rates with roflumilast treatment among patients hospitalized for chronic obstructive pulmonary disease
por: Fu, Alex Z, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_i6u0ckghmgii79h44c3flot791